ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,555.74
      -0.16%
      US Tech 100
      19,129.20
      -0.91%
      Dow Jones
      40,358.09
      -0.14%
      Brent Oil
      80.775
      -0.91%
      Bitcoin
      65,903.56
      -2.52%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Sagiment Biosciences Inc (SGMT) Quote

      Sagiment Biosciences Inc

      Sagiment Biosciences Inc (SGMT)

      NASDAQ
      3.27
      0.20
      (6.51%)
      At close: July 23 4:00PM
      Delayed by 15 minutes
      3.27
      0.00
      ( 0.00% )
      After Hours: 5:50PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      3.27
      Bid
      3.24
      Ask
      3.49
      Volume
      191,343
      3.03 Day's Range 3.28
      2.13 52 Week Range 20.71
      Market Cap
      99.386M
      Previous Close
      3.07
      Open
      3.06
      Last Trade
      11303
      @
      3.27
      Last Trade Time
      16:00:00
      Financial Volume
      $ 604,459
      VWAP
      3.159
      Average Volume (3m)
      514,884
      Shares Outstanding
      30,393,397
      Dividend Yield
      -
      PE Ratio
      -3.58
      Earnings Per Share (EPS)
      -0.92
      Revenue
      2M
      Net Profit
      -27.88M

      About Sagiment Biosciences Inc

      Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment ... Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.sagimet.com
      Headquarters
      Camden, Delaware, USA
      Founded
      1970
      Sagiment Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SGMT. The last closing price for Sagiment Biosciences was $3.07. Over the last year, Sagiment Biosciences shares have traded in a share price range of $ 2.13 to $ 20.71.

      Sagiment Biosciences currently has 30,393,397 shares outstanding. The market capitalization of Sagiment Biosciences is $93.31 million. Sagiment Biosciences has a price to earnings ratio (PE ratio) of -3.58.

      SGMT Latest News

      More News

      Form 144 - Report of proposed sale of securities

      2 hours ago
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      2 hours ago
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      2 hours ago
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      2 hours ago
      Edgar (US Regulatory)

      Form 8-K/A - Current report: [Amend]

      June 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 07 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 06 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 23 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 15 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.22-6.303724928373.493.712.953144993.31592196CS
      4-0.89-21.39423076924.164.23012.784211103.30791866CS
      12-0.95-22.51184834124.225.72.785148844.31070349CS
      26-15.15-82.247557003318.4218.92.788580806.4713201CS
      52-12.73-79.56251620.712.136411639.33687546CS
      156-12.23-78.903225806515.520.712.136318069.39628245CS
      260-12.23-78.903225806515.520.712.136318069.39628245CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ALLRAllarity Therapeutics Inc
      $ 0.284
      (70.57%)
      		39.96M
      NUZENuZee Inc
      $ 1.74
      (68.93%)
      		1.47M
      NIVFNewGenIvf Group Ltd
      $ 1.31
      (50.42%)
      		4.43M
      SLNASelina Hospitality PLC
      $ 0.0325
      (25.00%)
      		44.83M
      TSDDGraniteShares ETF Trust GraniteShares
      $ 10.25
      (13.89%)
      		772.54k
      VSTMVerastem Inc
      $ 2.65
      (-26.18%)
      		416.48k
      IONMAssure Holdings Corporation
      $ 1.99
      (-18.11%)
      		57.28k
      SLRXSalarius Pharmaceuticals Inc
      $ 2.17
      (-16.86%)
      		218.68k
      ALPPAlpine 4 Holdings Inc
      $ 0.4988
      (-16.85%)
      		305.14k
      CJETChijet Motor Company Inc
      $ 4.30
      (-15.35%)
      		90.79k
      SLNASelina Hospitality PLC
      $ 0.0325
      (25.00%)
      		44.83M
      ALLRAllarity Therapeutics Inc
      $ 0.284
      (70.57%)
      		39.96M
      TSLATesla Inc
      $ 229.70
      (-6.77%)
      		16.7M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 11.84
      (-13.58%)
      		15.12M
      HOLOMicroCloud Hologram Inc
      $ 0.5985
      (2.34%)
      		9.19M

      SGMT Discussion

      View Posts
      Pip611 Pip611 3 weeks ago
      Anyone know why this has been tanking so bad the last couple weeks?
      👍️0
      Monksdream Monksdream 3 months ago
      SGMT under $5
      👍️0
      AGORDON AGORDON 5 months ago
      Sagimet Biosciences (Nasdaq: SGMT $6.25)
      Buy recommendation.

      Market cap = $199M
      Cash = $210M+ (Just raised $112M through a secondary offering)
      Estimated cash burn = ($25)/year
      Lead product = Denifanstat an oral, once daily pill and selective first-in-class FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
      Jan. 22, 2024 announced positive topline results from Phase 2b clinical trial of Denifanstat in Biopsy-confirmed F2/FS NASH.
      The results are comparable to Madrigal's Resmitiron.
      Ascletis collaboration agreement = Potential $122M in milestone payments as well as tiered royalties ranging from percentages in the high single digits to mid-teens on future net sales of Denifanstat, which is referred to as ASC40 in Greater China
      Most AEs (adverse events) were Grade 1 or 2 (mild to moderate). There were no Grade 3 AEs.
      👍️0
      eneels01 eneels01 6 months ago
      See if $10 level holds. MC could drift upward later this year towards $1B area as company is similar to ETNB…
      👍️0
      dinogreeves dinogreeves 6 months ago
      Yup, got out at 16.25, thought they had enough in the coffers to push through this year. It was a good score while it lasted.
      👍️0
      TheFinalCD TheFinalCD 6 months ago
      Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
      https://newsfilter.io/articles/sagimet-biosciences-announces-pricing-of-public-offering-of-series-a-common-stock-c3511595df124183e48b41923f34e655

      Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
      https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-proposed-public-offering-series
      👍️0
      gail gail 6 months ago
      congrats!
      👍️0
      dinogreeves dinogreeves 6 months ago
      Only down 5% for after hours. Nothing to sweat over.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Three nice winners in my circle.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Looks like another run tomorrow.
      👍️0
      gail gail 6 months ago
      that was fun! i love “bar charts as…

      …

      ” i get a lot of good leads from that free website.
      👍️0
      gail gail 6 months ago
      hey dino, looks like we got a runner here, weeeee!!
      👍️0
      gail gail 6 months ago
      grabbed a few on the dip. hi all.
      👍️0
      dinogreeves dinogreeves 6 months ago
      Looks like easy 500% gainer today.
      👍️0
      dinogreeves dinogreeves 6 months ago
      What a great move and Baker Brothers in it, I simply got lucky at 11.38 with 2500 shares. Looks like billion dollar market cap is going to fetched here real soon.
      👍️0
      Awl416 Awl416 6 months ago
      That 20k block they filled at 9.69 before ripping

      Yummy
      👍️0
      Awl416 Awl416 6 months ago
      Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
      👍️0

      Your Recent History

      NASDAQ
      SGMT
      Sagiment Biosciences
      BOV
      MMMC34Q
      3M
      LSE
      BFSP
      Blackfinch Spring Vct
      COIN
      DOGEUSD
      Dogecoin
      AMEX
      AMPE
      Ampio Pharmaceuticals
      Delayed Upgrade Clock